MBRX Valuation

Moleculin Biotech Inc

Add to Watchlist

Advanced Chart

0.568

-0.029(-4.860%)1D

Overview
Forecast
Valuation
Earnings

MBRX Relative Valuation

MBRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MBRX is overvalued; if below, it's undervalued.

Historical Valuation

Moleculin Biotech Inc (MBRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.74. The fair price of Moleculin Biotech Inc (MBRX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.57

Fair

-0.39

Trailing

Forward

-0.28

EV/EBITDA

Moleculin Biotech Inc. (MBRX) has a current EV/EBITDA of -0.28. The 5-year average EV/EBITDA is 0.06. The thresholds are as follows: Strongly Undervalued below -0.35, Undervalued between -0.35 and -0.14, Fairly Valued between 0.27 and -0.14, Overvalued between 0.27 and 0.47, and Strongly Overvalued above 0.47. The current Forward EV/EBITDA of -0.28 falls within the Undervalued range.

-0.37

EV/EBIT

Moleculin Biotech Inc. (MBRX) has a current EV/EBIT of -0.37. The 5-year average EV/EBIT is -0.12. The thresholds are as follows: Strongly Undervalued below -2.53, Undervalued between -2.53 and -1.32, Fairly Valued between 1.09 and -1.32, Overvalued between 1.09 and 2.29, and Strongly Overvalued above 2.29. The current Forward EV/EBIT of -0.37 falls within the Historic Trend Line -Fairly Valued range.

0.00

Moleculin Biotech Inc. (MBRX) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

0.00

P/OCF

Moleculin Biotech Inc. (MBRX) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.16. The thresholds are as follows: Strongly Undervalued below -0.88, Undervalued between -0.88 and -0.52, Fairly Valued between 0.20 and -0.52, Overvalued between 0.20 and 0.56, and Strongly Overvalued above 0.56. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Moleculin Biotech Inc. (MBRX) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.88. The thresholds are as follows: Strongly Undervalued below -3.27, Undervalued between -3.27 and -2.07, Fairly Valued between 0.32 and -2.07, Overvalued between 0.32 and 1.51, and Strongly Overvalued above 1.51. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Moleculin Biotech Inc (MBRX) has a current Price-to-Book (P/B) ratio of -2.36. Compared to its 3-year average P/B ratio of 16.91 , the current P/B ratio is approximately -113.97% higher. Relative to its 5-year average P/B ratio of 10.75, the current P/B ratio is about -121.99% higher. Moleculin Biotech Inc (MBRX) has a Forward Free Cash Flow (FCF) yield of approximately -118.21%. Compared to its 3-year average FCF yield of -217.02%, the current FCF yield is approximately -45.53% lower. Relative to its 5-year average FCF yield of -142.69% , the current FCF yield is about -17.15% lower.

-2.52

P/B

Median3y

16.91

Median5y

10.75

-125.72

FCF Yield

Median3y

-217.02

Median5y

-142.69

Competitors Valuation Multiple

The average P/S ratio for MBRX's competitors is 145.18, providing a benchmark for relative valuation. Moleculin Biotech Inc Corp (MBRX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MBRX.O

Moleculin Biotech Inc

Relmada Therapeutics Inc

Loss

20.81M

LSTA.O

Lisata Therapeutics Inc

Performance Decomposition

Market capitalization of MBRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MBRX in the past 1 year is driven by Unknown.